

APERTURE HEALTH, INC.

Issuer's Updated Disclosure Obligations

For the three and six months ended June 30, 2012

Part A **General Company Information**

Item 1 **The Name of the Issuer**

The name of the issuer is Aperture Health, Inc. ("Aperture") which had changed its name from flexSCAN, Inc. in March of 2008.

Aperture is the surviving entity of a merger transaction with Triad Therapeutics, Inc., a Delaware Corporation, which occurred on July 18, 2011 ("Triad" is a wholly owned subsidiary).

Rental payments were past due and the landlord filed suit against Triad. The Company ultimately ceased operations of its office and pharmacy in Fairfield, New Jersey on June 30, 2012 and in a change of strategy, whereby Aperture, the parent, will dedicate its future financial and human resources to the recently announced proposed acquisition of Doctors on Call and the expansion of the companies as more fully described in item 9. Pursuant to the terms of the lease, the landlord took possession of all property and equipment that was in the office on June 30, 2012.

Item 2 **Address of the Issuer**

Triad Therapeutics, Inc.
P.O. Box 100
Pine Brook, NJ 07058

Item 3. **The Jurisdiction and Date of the Issuer's Incorporation**

Aperture Health, Inc., a Nevada corporation, was incorporated In Feb. 2001

Part B **Share Structure**

Item 4 **The exact title and class of Securities outstanding.**

Common Stock, Cusip #03753T 208, Trading Symbol: "APRE"

Item 5 **Par or stated value and description of the security.**

Common Shares have a Par Value of \$0.001 per share. Each outstanding share of Common Stock is entitled to one vote. Dividends are authorized by the Company's Board of Directors in accordance with Nevada law. Shareholders have no extraordinary material rights other than those authorized by law, and no provision in the issuer's bylaws or charter would delay, defer or prevent a change in control of the Company.

Item 6 **Number of Securities Outstanding**

- Common Shares: As of June 30, 2012, the Company had 150 million shares of Common Stock authorized with 49,575,954 shares outstanding, of which, 23,446,492 shares are outstanding as the "public float". There are 782 shareholders of record as of June 30, 2012.
- Preferred Shares: The Company is authorized to issue up to 10,000,000 shares of Preferred stock. As of June 30, 2012, no shares of Company Preferred Stock had been issued.

Item 7 Transfer Agent

The Company's transfer agent is Olde Monmouth Stock Transfer Co. Inc. ("Olde Monmouth"). Olde Monmouth is registered under the Exchange Act and is regulated by the Securities and Exchange Commission. Olde Monmouth's contact information is:

Olde Monmouth Stock Transfer Co. Inc.
200 Memorial Parkway
Atlantic Highlands, NJ 07716
Phone: 732-872-2727
Fax: 732-872-2728
<http://www.oldemonmouth.com/>

Part C Business Information

Item 8 The nature of the issuer's business

A. Business Development

- 1) Form of Organization Aperture Health, Inc. ("the Company") is a corporation organized under the laws of the state of Nevada.
- 2) Year of Formation The Company was incorporated on February 13, 2001.
- 3) Fiscal Year The Company's fiscal year ends on June 30. The Company's sole operating entity, Triad Therapeutics, Inc., has maintained a December 31 fiscal year since inception.
- 4) Bankruptcy Neither the Company, nor any of its predecessor entities has ever been in bankruptcy, receivership or any similar proceeding.
- 5) Material Reclassifications and Mergers On September 9, 2005, the Company, then called flexSCAN, Inc. ("flexSCAN"), effected a reverse merger with Fuel Corporation of America, Inc. ("FCA") where flexSCAN was the surviving entity. FCA was a Nevada Corporation. In March 2008, the Company's name was changed from flexSCAN, Inc. to Aperture Health, Inc. ("Aperture"). Triad Therapeutics, Inc. ("Triad") was incorporated in Delaware in 2007. On July 18, 2011, Triad merged into the Company via a reverse merger transaction.
- 6) Defaults on indebtedness The Company is in default on the following indebtedness:

- a. In May of 2006, Aperture entered into a 10% Promissory Note with Mr. Francis Pisano, a former executive with the Company, for the amount of \$35,000. The Note matured on August 4, 2008 and the Company has been in default on the Note with no payments being made. In accordance with the reverse merger agreement, Triad has assumed \$25,000 of the outstanding debt to Mr. Pisano. Subsequent to this, Mr. Pisano executed an Agreement between Mr. Robert Rubin, Mrs. Miriam Gold, and the Corporate Communications Group, Inc. to purchase the Note in its entirety. The Note Assignment Agreements and Conversion Agreements are posted on Aperture's OTC site under Legal Opinion and Conversion Notes posted on 12/23/11. On December 5, 2011, the Company entered into Note Conversion Agreements between Corporate Communications Group, Inc., Robert Rubin and Miriam Gold, for the ability to convert all of the \$25,000 principal outstanding debt on the note to 25,000,000 shares of free trading common stock of the Company.
- b. On April 24, 2009, Triad issued ten notes to its principal lenders with a total face amount of \$834,217. The notes matured on March 1, 2010. As of June 30, 2012, Triad has not made any payments on these Notes.
- c. On November 18th, 2010, Triad issued ten additional Notes to the same lenders with a face amount of \$148,000. The notes matured on October 31, 2011 and as of June 30, 2012 there had been no payments on these Notes.
- d. On May 31, 2011, Triad issued a note to Visual Displays, Inc. with a face amount of \$100,000. The note matured on September 30, 2011. As of June 30, 2012, Triad has paid back \$50,000 of the outstanding liability to Visual Displays, Inc.
- e. Triad Therapeutics remains in arrears with respect to certain payroll taxes, related penalties and interest assessed thereon for both Federal and New Jersey State Trust Funds. Federal liens and levies have been executed on certain corporate bank accounts and some contracted payers for receivables. Management had been in communication with both the I.R.S. and New Jersey State agents regarding Triad's outstanding tax debt, with an intent to have an arrangement agreed upon wherein all amounts due would be paid over a period of time pursuant to a payment plan. Such payments would be made with a portion of the proceeds from additional corporate funding when such funding is agreed upon. As of June 30, 2012, the Company remains in arrears for approximately \$400,000 in Federal 941 taxes and related penalties and interest as well as New Jersey State withholding taxes and New Jersey labor workforce taxes and related penalties and interest.
- f. In December of 2010, Triad issued a Promissory Loan Agreement to Mr. Louis Juliano with a face amount of \$30,000 plus interest and as of June 30, 2012, Triad has not made any payments to Mr. Juliano.
- g. Aperture intends to recognize any individual or corporate outstanding debt relating to past loans and debentures for accounting purposes as required under U.S.GAAP. Further, the Merger Agreement by and between Aperture Health, Inc. and Triad Therapeutics, Inc., contemplated that there shall not be greater than \$25,000 of existing Aperture debt post merger as a legal

and binding liability assumed by the post merger Company. Notwithstanding the foregoing, the current Board of Directors and Management of Aperture Health, Inc. and the Company's wholly owned subsidiary, Triad Therapeutics, Inc., will in its sole discretion, evaluate and reorganize and/or resolve in a commercially reasonable manner, the prior existing debt recognized for accounting purposes only. Resolution may mean the following, including without limitation, forgiveness of debt or conversion of debt to common stock. As of the merger date, Aperture had outstanding Note obligations of \$1,275,000 as reflected in the September 2011, Consolidated Financials posted on the Company's OTC site and in the December, 2011 Consolidated Financial Data attached to this Disclosure Document. As of June 30, 2012, the balance owed on the Aperture Notes is \$1,250,000 which accounts for the \$25,000 conversion of the Pisano' Note detailed in above.

- h. *On Aug. 10, 2011, Triad issued a promissory note to Brigadier Investment Group, maturing 12/31/2011, with Triad being obligated to pay a total of \$60,000 (a \$50,000 note plus a \$10,000 origination fee). In addition, Triad entered into a short term consulting agreement with Brigadier, whereby Triad agreed to pay \$40,000 for various services through 12/31/2011. As of June 30, 2012, Triad has paid back \$50,000 of the outstanding liability and remains in default of the terms of the Note owing another \$50,000. Copies of both the Note and Consulting Agreement were posted in Aperture's OTC Financial Section.*

- i. *On December 15, 2011, Aperture issued a Promissory Note to Mclain Amarillo III, LLC, maturing on February 15, 2012 with Aperture being obligated to pay a total of \$120,000 (a \$100,000 Note plus a \$20,000 origination fee). The obligation has been in default since February 15 2012. Aperture also entered into a short term Consulting Agreement with Mclain Amarillo III, LLC whereby Aperture agreed to pay \$80,000 for various consulting services through 06/30/2012. Copies of both the Note and Consulting Agreement are posted in Aperture's OTC Financial Section.*

- 7) Change of Control In connection with the reverse merger of Triad into the Company, the Triad Shareholders received a controlling interest in the Company. Certificates of merger have been obtained from the Nevada and Delaware Secretaries of State.

- 8) Increase of 10% or more of the same class of outstanding equity securities: In September of 2011, the Company issued 21 million new common shares to executive management, various employees and outside individuals and entities as consideration for services rendered. In December of 2011, the Company issued 5,050,000 new common shares in relation to the "Pisano" Promissory Note conversion detailed above in #6a (defaults on indebtedness). From January 1, 2012 through June 30, 2012, the Company issued an additional 16,313,000 new common shares in relation to the "Pisano" Promissory Note conversion detailed above in Section 6(a).

- 9) Stock Splits: On September 13, 2011, the Company executed a 1:500 reverse stock split.
- 10) Delisting: The Company has never had any securities delisted or deleted from any exchange.
- 11) Material legal Proceedings The Company is involved in the following legal proceedings:
 - a. The Company is indebted to the United States Treasury and the State of New Jersey for approximately \$400,000, including penalties, unpaid wages and interest as of June 30, 2011. Federal Tax Liens and Levies have attached to Triad's corporate bank accounts and receivables. Executive Management have been in communication with both IRS and NJ State agents regarding the company's outstanding tax debt with the intent to have such amounts paid over a period of time pursuant to an agreement as described in 6(e) with a portion of the proceeds from Aperture Health's further investor funding.
 - b. Integrated Medical Systems, a vendor of IV therapy supplies and pump rentals, sued Triad for unpaid invoices totaling \$144,128. In February 2012, a Default Judgment was entered against Triad.
 - c. A Judgment for \$5,000 was placed against Triad in NJ for a lawsuit by Medical Specialties, Inc., a vendor of IV supplies to Triad.
 - d. PromptCare, Inc., a New Jersey-based home IV therapy company, sued the Company alleging violation of a non-compete agreement between PromptCare and a former employee. The Company agreed to pay \$20,000 to settle this matter. As of June 30, 2012, Triad had paid \$3,000.
 - e. Professional Home Infusion, a Nursing services vendor claimed amounts due of \$2,687.
 - f. Impulse Courier has sued Triad for outstanding invoices totaling \$2,592.

There are numerous other law suits and the Company has no current source of financing and is therefore unable to negotiate any agreement of settlement with the vendors.

B. Business of Issuer

Neither Aperture Health, Inc. nor Triad Therapeutics, Inc. have been a "shell company." Aperture Health, Inc. is the sole owner of Triad Therapeutics, Inc.

The Company previously participated in both Federal and State healthcare reimbursement programs (Medicare and Medicaid) and was subject to changes (both positive and negative) in reimbursement or coverage from these and other sources primarily in the home infusion business. The Company had no expenses relating to research and development activities.

The Company ceased all operations effective June 30, 2012 and is in discussions with Docs on Call as to

Created on 11/27/2012 9:33:00 PM

a merger transaction between the companies.

As of June 30, 2012, the Company had one full time employee (Jim Hennig).

Item 9. The nature of services to be offered

Triad previously provided specialized home health services to patients and was a fully accredited home IV therapy company. As stated above, the Company ceased all operations on June 30, 2012 and Aperture intends to focus on the proposed acquisition with Doctors on Call and the planned expansion including full service clinics capable of urgent care with lab, X-ray and exam rooms each having its own full service individual pharmacy in each center. The pharmacies will provide oral meds for patients on a retail level and provide IV services for patients needing IV therapy at the center as well as in the home where required.

Item 10 The Company's facilities

The Company previously leased a 9,000 square foot fully licensed, equipped and JCAHO accredited facility in New Jersey. Pursuant to the lease terms and the landlords' instructions, the facility was closed and the Company ceased all operations effective June 30, 2012.

PART D Management Structure and Financial Information

Item 11 The name of the Chief Executive Officer, members of the Board of Directors and control person

Aperture Health, Inc.'s President, CEO, Chairman and Pharmacist-in-Charge is James E. Hennig, R. Ph. Mr. Hennig is a New Jersey Registered Pharmacist with over 25 years of home IV therapy industry experience. His responsibilities have included business development, sales and marketing, clinical operations, middle and executive management roles for public and private healthcare companies ranging from \$5M to \$100M in revenues. For his services to the company Mr. Hennig had an annual salary of \$180,000 of which \$90,000 is unpaid as of June 30, 2012 and he is also owed \$90,000 from 2011. Mr. Hennig owns 10,000,000 shares of Company Common Stock.

Mr. Arnold Silver is a member of the Board of Directors of Aperture Health, Inc. Mr. Silver brings strength to Aperture's Board from his 27 years of experience in the ownership/operations of multiple restaurant enterprises.

Mr. Lance Friedman is a director of the Company and was most recently a partner in Cooper Beech Equity and Corinthian Holdings, both Merchant Banking firms. He previously served as Managing Director/Partner of EGL Holdings, Inc., a venture capital and boutique investment banking concern in charge of healthcare practice and investments. Mr. Friedman has served in executive operational capacities for various companies including Wireless MD, M2Verticom, Brooklyn Bottling and Canning Corp, and Fletcher-Flora Health care Systems. He holds a BA from American University and a JD from Benjamin Cardozo School of Law, Yeshiva University. Mr. Friedman owns 3,000,000 shares of Company common stock.

Mr. Larry Friedman serves as Aperture Health's Secretary. Mr. Friedman has maintained Triad's unaudited financial records since inception in 2007 through March 31, 2012.. He holds a BS in Accountancy from NYU in 1954 and a State of NY CPA since 1964. Mr. Friedman managed several public accounting firms from 1966 through 1988. Since retiring in 1988, Mr. Friedman has performed forensic accounting services on a contract basis. Mr. David Barnes of Boynton Beach prepared the statements for the six months ended June 30, 2012

To the Company's knowledge there are no active past, current and/or pending legal or disciplinary histories associated with any of the aforementioned individuals that would prevent them from fulfilling their duties on behalf of the Company.

Triad has engaged in the following Related Party Transaction: In December 2010, Triad entered into a Promissory Loan Agreement with Mr. Louis Juliano totaling \$30,000 plus interest. Mr. Juliano is the father of Serena Juliano, an ex-employee and stockholder of Aperture Health, Inc. As of June 30, 2012, no payments have been made to Mr. Juliano.

There are no Conflict of Interest issues to report.

Items 12 & 13: Financial Information for the most recent and 2 preceding fiscal years.

Unaudited financial results for prior periods are posted on the company's OTC site under the financial section and identified as "preliminary results", "interim financial report" and "quarterly report".

Unaudited Financial Results for the three and six months ended June 30, 2012 are attached to the end of this Updated Disclosure Document,

Item 14 Beneficial Owners.

As of June 30, 2012, the following are the owners of more than 5% of Aperture Health's stock:

James Hennig, the company's, CEO and President, owns 10,000,000 shares of Company Common Stock.

Lance Friedman owns 3,000,000 shares of Company Common Stock and is the secretary for the Company. The above individuals may be contacted by U S M a i l care of the Company at P.O. Box 100 Pine Brook, NJ 07058

Gersten Savage LLP owns 4 Million shares of Company Common Stock and is can be reached at 600 Lexington Ave. 9th Floor, New York, NY 10022 (212)-752-9700, the firm had previously provided legal services relating to Triad and Aperture's reverse merger and other corporate matters.

Item 15 Outside providers that advise the issuer on matters relating to operations, business development and disclosure.

Counsel: Gersten-Savage, LLP (address and contact listed above)

Counsel:

David Sayid: Sayid and Associates LLP – 212-262-1166 – fax 212-247-7535
408 West 57th Street Ste 8E
New York, New York 10019

M. David Sayid is the Managing Partner of Sayid and Associates LLP. The firm is engaged in the practice of law in the State of New York and has been retained to review certain letters and documents related to the Companies. Mr. Sayid is authorized to practice law in New York, Massachusetts and Pennsylvania as well as before the United States Supreme Court and the Court of Appeals. Mr. Sayid is also authorized to practice before the United States Securities and Exchange Commission.

The Company has utilized the services of Mr. Larry Friedman for all accounting needs including payables management, tax filings and unaudited financial reports through March 2012. Mr. David Barnes of Boynton Beach, FL prepared the June report. His contact number is 425-503-9400.

Upon finalizing a merger agreement between Aperture and Doctors on Call, the Company intends to engage the accounting firm of EFP Rotenberg, LLP to perform an audit of financial statements for the Companies. Their corporate offices are located at 280 Kenneth Drive, Suite 100, Rochester, NY 14623.

Item 16 Management's discussion and analysis of financial condition and results of operations.

Triad Therapeutics, Inc. was formed in 2007 and merged with Aperture Health, Inc. on July 18, 2011.

Negative developments within the investment banking community associated with the continued downturn in the US economy in late 2011 and in the first half of 2012 caused a downward pressure on the company's ability to aggressively market services and expand operations. This was primarily due to the company not being able to obtain sufficient funding to maintain a hi-tech IV therapy pharmacy business in a highly competitive industry. That coupled with industry standard delays in reimbursement through insurance payers made it impossible to achieve a break-even point quickly. Management then determined that a change in strategy as mentioned in item 9 was necessary.

Attached to the end of this Quarterly Updated Disclosure Document are unaudited financial statements for the three and six months ended June 30, 2012.

The Company recorded revenue of \$56,934 and \$176,587 respectively for the three and six months with losses of (\$486,032) and (\$820,109).

The Company has no Off-Balance Sheet arrangements.

Effective June 30, 2012, the Company ceased its business and intends on partnering with Doctors on Call.

Part E. Issuance History

Item 17 List of Securities Offerings and Shares Issued for Services.

The Company has not engaged in any securities offerings in the last two years.

In connection with the July 18, 2011 reverse merger of Triad into the Company, the Company issued 21 million restricted common shares to certain employees and service providers for services provided to the Company. The majority recipients are listed in the Beneficial Owners Section, above.

In connection with the Pisano Note conversion (detailed in Sect6(a) above), the Company, on various dates since 12/14/11 issued a total of 21,363,000 free trading shares with an additional 3,637,000 remaining to be issued as requested by the principals who acquired the note. Copies of the Legal Opinion and Conversion Documents are posted on the APRE OTC site under the financial tab with a publish date of December 23, 2011 labeled as "Legal Opinion and Conversion Notes".

Part F. Exhibits

Item 18 Material Contracts

In its normal course of business, the Company had entered into contracts for insurance provider networks and to purchase necessary supplies, and nursing services.

All Agreements and Notes disclosed in Section A #6 (defaults on indebtedness) above are posted on the Company's OTC site in the financial section.

Item 19 Articles of Incorporation and Bylaws

Please see Aperture Health's Articles of Incorporation and Bylaws filed under separate postings on the OTC Disclosure Service. No changes or amendments to the Articles or Bylaws have occurred that have not been previously reported.

Item 20 Purchases of Equity Securities by the Issuer


The Company has not purchased shares or other units of any class of its own equity securities, nor has any affiliated purchaser on the Company's behalf.

Item 21 Issuer's Certifications

I, James E. Hennig, Chief Executive Officer of Aperture Health, Inc. certify that:

1. I have reviewed this supplemental information statement of Aperture Health, Inc., a Nevada Corporation.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which statements were made, not misleading with respect to the period covered by this disclosure statement, and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in the disclosure statement.
4. Triad, the operating company, ceased all operations effective June 30, 2012.

Date: November 27, 2012



James E. Hennig, R. Ph., President and CEO

Aperture Health, Inc...

Aperture Health, Inc.

Consolidated Statement of Operations
For the Three and Six Months
Ended June 30, 2012

	<u>THREE MONTHS</u>	<u>SIX MONTHS</u>
Revenue	\$ 56,934.	\$ 176,587
Cost of goods sold	51,453	124,374
Gross Profit	5,482	52,213
Administrative expenses	(408,787)	(767,662)
Interest and finance expenses	(82,727)	(104,660)
Loss before income taxes	(486,032)	(820,109)
Income tax expense		
Net Loss	\$ (486,032)	\$ (820,109)

Aperture Health, Inc.

Consolidated Balance Sheet

As at June 30, 2012

Unaudited

Assets:	
Cash	\$ 2,898
Accounts receivable	18,884
Prepaid and other current assets	0
Total current assets	21,781
Fixed assets	0
Security deposits	0
Intangible assets	0
Total assets	21,781
Current Liabilities:	
Due to Shareholder	
Accounts payable	228,357
Due to officer	678,155
Notes payable	27,986
Accrued expenses	1,478,090
Payroll tax liabilities	295,229
Other	393,025
	5,703
Total current Liabilities	3,106,546
Long term notes payable to shareholders	1,248,998
Total liabilities	4,355,544
Shareholders' equity:	
Common Stock outstanding	49,575
Capital in excess of par	136,474
Total Shareholder's Equity	186,049
Accumulated deficit	(4,519,813)
Shareholder's (deficiency)	(4,333,763)
Total liabilities and Shareholder's deficiency	\$ 21,781

Aperture Health, Inc.

Consolidated Balance Sheet

As at June 30, 2012

Unaudited

Aperture Health, Inc.
 Consolidated Statement of Cash Flows
 For the Six Months Ended June 30, 2012
 Unaudited

<hr/>		
<hr/>		
<hr/>		
<hr/>		
Cash provided (used for): Operating activities:		
Net income for the period	\$ (820,109)	720,109
Changes in non-cash working capital:		
Accounts receivable	112,789	
Prepaid and other current assets	71,877	
Accounts payable	126,258	
Due to Shareholder and officer	177,900	
Accrued expenses	150,252	
Payroll tax liabilities	148,163	
Other current liabilities	0	
Net cash provided by (used in) operating activities	(32,870)	
Investing activities:		
Fixed Assets: Computer Hardware etc.	97,430	
Net cash used in Investing activities	97,430	
Financing activities:		
Issuance of Common Stock	32,050	
Borrowings (repayments) pursuant to Notes payable	(96,976)	
Net cash provided by financing activities	(64,926)	
<hr/>		
Net increase (decrease) in cash and cash equivalents	(369)	
Cash and cash equivalents beginning of period	\$ 3,264	
Cash and cash equivalents end of period	\$ 2,898	

Aperture Health, Inc.

Consolidated Statement of Shareholders' Deficiency
 For the six months ended June 30, 2012
 Unaudited

	Common Stock		Additional Paid In Capital	Accumulated Deficit	Total Shareholders' Equity
	Shares	Amount			
Balance as of December 31, 2010	26,050,631	26,051	127,949	(2,999,444)	(2,845,444)
Share issuance pursuant to recapitalization	162,323	162	(162)		
Net loss for the year ended December 31, 2011				(700,259)	(700,259)
Issuance of shares in the six months ended June 30, 2012	23,363,000	23,363	8,687		32,050
Net loss for six months ended June 30, 2012				(820,109)	(820,109)
Balance as of June 30, 2012	49,575,954	49,576	136,474	(4,519,813)	(4,333,763)

APERTURE HEALTH, INC.

Notes to Unaudited Consolidated Financial Statements

06/30/2012

Note 1: Organization-Business Activities

Aperture Health Inc. (The Company), a Nevada Corporation, was incorporated on Sept. 08, 2005. On July 18, 2011, Triad Therapeutics Inc. (Triad) merged into The Company via a reverse merger transaction as consideration for all of the issued and outstanding shares of Triad. The Triad shareholders received a 51% controlling interest in The Company. On Sept. 13, 2011, the Company executed a 1 : 500 reverse stock split. Triad is the sole operating entity. Triad was incorporated in Delaware in 2007.

The Company's primary line of business was providing Home intravenous therapy services to patients requiring specialized intravenous medication and nursing services. Triad sold these services throughout the states of New Jersey, New York and Connecticut.

The Company ceased operations effective June 30, 2012. All property and equipment was abandoned and left in the premises pursuant to instructions from the landlord and such assets have been reduced to a zero value in the Balance Sheet.

Note 2: Basis of Presentation:

The Consolidated Financial data contained herein represent Triad as the operating company, as Aperture Health had no operations during this period.

The Consolidated Financial information at June 30, 2012 is unaudited but includes all adjustments (of normal recurring adjustments and asset write offs) which, in the opinion of management, are necessary to state fairly the consolidated financial information set forth therein, in accordance with generally accepted accounting principles.

The acquisition of Triad by the Company was accounted for by a reverse merger, whereby Triad is the continuing entity for financial reporting purposes and is deemed, for accounting purposes, to be the acquirer of the Company. In accordance with the applicable accounting guidance for accounting for the business combination as a reverse merger, Triad is deemed to have undergone a recapitalization, whereby Triad is deemed to have issued equity to the Company's common stock holders. Accordingly, although the Company, as Triad's legal parent company, was deemed to have legally acquired Triad, in accordance with the applicable accounting guidance for accounting for the transaction as a reverse merger and recapitalization, Triad is the surviving entity for accounting purposes and its assets and liabilities are recorded at their historical carrying amounts with no goodwill or other intangible assets recorded as a result of the accounting merger with the Company. All intercompany balances and transactions have been eliminated upon consolidation.

Note 3: Property and Equipment:

Property and Equipment was stated at cost. Depreciation was computed utilizing the straight line method over the life term of the asset. All such assets were written off as of June 30, 2012 and the loss was recorded in Operations.

Note 4: Intangible Assets:

Pre-operating expenses were recorded at cost and were being written off over their 15 year life. All such expenses were written off in full with the write off of other assets as of June 30, 2012.

Note 5: Notes Payable:

a). On Dec. 20, 2010, Triad issued a promissory note to Mr. L. Juliano with a face amount of \$30,000 plus interest at 5% per annum. Triad has been in default according to the repayment terms of the loan.

b). On May 31, 2011, Triad issued a promissory note to Visual Displays, Inc., with a face value of \$50,000 maturing 09/30/2011 with Triad being obligated to pay a total of \$100,000 (the \$50,000 note plus a \$50,000 loan origination fee.) The obligation is currently in default. The balance as of June 30, 2012 was \$65,000.

c). On Aug. 10, 2011, Triad issued a promissory note to Brigadier Investment Group, maturing 12/31/2011, with Triad being obligated to pay a total of \$60,000 (a \$50,000 note plus a \$10,000 origination fee). The obligation is currently in default. As of June 30, 2012, \$50,000 had been paid.

Triad also entered into a short term consulting agreement with Brigadier, whereby Triad agreed to pay \$40,000 for various services provided through 12/31/2011.

d). As of the merger date, Aperture had outstanding note obligations of \$1,275,000. The Company issued 25,000,000 free trading common shares at par value in consideration for \$25,000 of one of the notes. The current balance of the notes total \$1,250,000.

e). On Dec. 15, 2011, Aperture issued a promissory note to Mclain Amarillo III LLC, maturing 02/15/2012, with Aperture being obligated to pay a total of \$120,000.00 (a \$100,000 note plus a \$20,000 origination fee). The obligation is currently in default.

Aperture also entered into a short term consulting agreement with Mclain Amarillo III LLC, whereby Aperture agreed to pay \$80,000 for various services provided through 06/30/2012. No payments have been made on this Note as of the filing date of this report.

Note 6: Taxes:

Triad remains in arrears with respect to payroll tax payments for Federal and New Jersey and penalties and interest assessed thereon. Federal liens and levies have been executed on certain corporate bank accounts and some contracted payers for receivables. Management has been in communication with both the I.R.S. and New Jersey State agents as well as the New Jersey Department of Labor regarding Triad's outstanding tax debt and unpaid salaries which, including interest and penalties, is approximately \$400,000. The intention would be to have amounts paid over a period of time by entering into a long-term payment arrangement funded by additional loans from the Company's majority debt holders and / or a portion of proceeds obtained from an offering of securities.

Note 7: Litigation:

A). A law suit was filed against Triad in late 2011, alleging a violation of a non-compete agreement having to do with a t h e n current Triad employee and former employer. Triad agreed to pay \$20,000 in settlement, payable \$10,000 on 11/01/2011 and \$10,000 on 02/01/2012. As of June 30, 2012, Triad had paid \$3,000 towards this settlement and the obligation is in default.

In addition to the litigation discussed herein, there are numerous other law suits and claims that have been filed against the Company but currently, there is no funding available to pay or to negotiate settlements with these vendors. Please see page 5.

Note 8: Leasehold:

Triad had leased 9,000-sq feet of office space including a fully licensed equipped and JACHO accredited pharmacy at a monthly rental of \$ 10,833 plus CAM and certain real estate taxes. Triad was in arrears with lease payments and was evicted by the landlord effective June 30, 2012.

Note 9: Bad Debt Write off:

On April 20, 2012 Infusion Solutions Inc., a customer, filed for Chapter 7 Bankruptcy. The Company has therefore recorded a bad debt in the amount of \$23,137.

Note 10: Going Concern Disclaimer

The Company ceased operations effective June 30, 2012. All property and equipment was abandoned and left in the premises pursuant to instructions from the landlord and such assets have been reduced to a zero value.